How long does it take to become resistant to Erdafitinib?

Erdafitinib (Erdafitinib) is a drug used to treat advanced or metastatic urothelial carcinoma with FGFR (fibroblast growth factor receptor) gene mutations. The development of drug resistance is a complex process that may vary from patient to patient. Although erdafitinib works against FGFR gene mutations, new mutations may lead to the emergence of drug resistance.

Erdafitinib is a small molecule pan-FGFR inhibitor that has shown clinical benefit in several trials with acceptable safety and tolerability. In April 2019, it became the first FGFR kinase inhibitor to receive accelerated approval from the FDA for patients with platinum-refractory advanced UC. While it expands the scope of treatment beyond chemotherapy and/or immunotherapy, more trial results are needed to establish evidence of its utility. There may be different subpopulations of cells within the tumor, some of which may be resistant to drugs, leading to the development of drug resistance. Long-term use of erdafitinib may lead to the development of drug resistance. Each patient's response time to the drug may vary.

The original version of erdafitinib has not yet been launched in China, so it cannot be covered by medical insurance. The original version of erdafitinib currently sold in Hong Kong may cost more than 20,000 yuan per box of specifications 4mg*14 tablets (the price may fluctuate due to exchange rates). Cheaper erdafitinib generic drugs produced by other pharmaceutical factories are also sold overseas. The pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of 4mg*60 tablets produced by a Bangladeshi pharmaceutical factory may be more than 3,000 yuan per box (the price may fluctuate due to exchange rates).